Landmark CVBD Prevention Field Study Demonstrates Benefits of Advantix(R) Spot-on Treatment for Dogs

Monheim, Germany, July 6, 2010 (ots/PRNewswire) - The findings of a
landmark Canine Vector Borne Disease (CVBD) prevention field study,
published in Veterinary Parasitology today, showed the remarkable
repelling efficacy of Advantix(R) in protecting dogs from ticks and
sand flies and thereby reducing the risk of transmission from the
potentially deadly diseases they spread.

This highly comprehensive study, conducted over two years by the
team of Prof. Domenico Otranto of the Faculty of Veterinary Medicine
(Universita degli Studi di Bari) Italy, with diagnostic support from
the team of Dr. Edward Breitschwerdt at the North Carolina State
University, USA, found that dogs treated regularly with Advantix(R)
spot-on had a greater than 90% reduction in CVBD cases, including a
100% reduction in new cases of potentially deadly leishmaniosis and a
94.6% decrease in ehrlichiosis.

The study also found that Advantix(R) provided 97.9% protection
against tick infestation, compared to untreated dogs, where 100% were
infested at the peak of the season. The level of protection offered
by Advantix(R) was all the more notable because of the particularly
large numbers of ticks and sand flies and high prevalence of
associated diseases like leishmaniosis or babesiosis in the area of
the study.

According to Prof. Otranto, "Our study shows the importance of
protecting dogs with an effective treatment that repels as well as
kills parasites like ticks and sand flies. Despite the high challenge
faced by the dogs in our study, nearly all our treated dogs remained
free from ticks throughout most of the study, and more than 90%
remained free from CVBDs for the whole study time."

"Because we included naive sentinel beagles in the study, we were
also able to model what would happen to dogs travelling to areas
where CVBDs are present. We found that by the end of the study, only
the Advantix(R)-treated beagles remained protected from infection,
while 80% of the untreated beagles were infected with a CVBD. This
demonstrates the very real need to protect dogs that are travelling
to endemic areas", continued Prof. Otranto.

The study showed some interesting results with dogs that were
positive with CVBDs when they entered the study. Of these, half of
those treated with Advantix(R) were negative for CVBDs at the end of
treatment, compared with only 13% of untreated dogs. This suggests
the potential for natural clearance of CVBDs if a repellent treatment
is used to prevent new transmissions.

This study was extremely comprehensive, studying both indigenous
and introduced naive puppies, monitoring for several CVBDs and
working with Dr. Breitschwerdt's team in the USA to use highly
sensitive molecular testing techniques to ensure optimal diagnostic
accuracy. According to Dr. Breitschwerdt, "This is the most
comprehensive study, to my knowledge, ever conducted testing the
efficacy of a repellent ectoparasiticide to prevent the transmission
of a spectrum of CVBDs in young dogs."

"Thanks to this study we can see just how effective a treatment
that repels as well as kills can be. With the increasing risk of
CVBDs, I'd urge all pet owners to speak to their vets about finding
the right tick-prevention strategy for their dog especially when
travelling into endemic areas," said leading parasitology expert, Dr.
Luis Cardoso of the University of Tras-os-Montes e Alto Douro,
Portugal.

Sarah Weston, Global Veterinary Services of Bayer Animal Health
said "It is important to realise that with globalisation, climate
change and the increase in pet travel, many more pets now need to be
protected from these diseases that can be potentially fatal for both
pets and humans. This study demonstrates that using Advantix(R) is an
effective way to protect pets from bites of ticks and sand flies,
reducing the risk of CVBD transmission.

Bayer Animal Health has been researching in the field of
parastitology over the last 100 years. The company is committed to
advancing the scientific understanding of parasitology by supporting
the annual CVBD World Forum and an online guide that is educating pet
owners around the world on the dangers posed by parasites
http://www.youtube.com/user/parasitesundercover1.

For more information on canine vector-borne diseases and the CVBD
World Forum, please visit http://www.CVBD.org.

To view the full MMR release, including video interviews with the
study investigator and leading veterinary experts, please click here
(http://bit.ly/CVBDprevention )

About the study

The study was conducted over two parasite seasons, and ran from
March 2008 to October 2009. It looked at two types of dog, puppies
indigenous to the area and naive sentinel beagle puppies.

A total of 111 indigenous dogs were enrolled alongside 20 naive
sentinel beagles. The dogs were randomly assigned in equal numbers to
either a treated group receiving Advantix(R) at 3-weekly intervals
for the course of the study or a control group receiving no
treatment.

Please see the video 'Prof Otranto - Study design' for more
information from Prof. Otranto on the study design.

The backgrounder also includes additional information on the
study and the original study paper is available via the full MMR
release.

About Bayer HealthCare

Bayer HealthCare, a subsidiary of Bayer AG, is one of the world's
leading, innovative companies in the healthcare and medical products
industry and is based in Leverkusen, Germany. The company combines
the global activities of the Animal Health, Bayer Schering Pharma,
Consumer Care and Medical Care divisions. Bayer HealthCare's aim is
to discover and manufacture products that will improve human and
animal health worldwide. Find more information at
http://www.bayerhealthcare.com.

With a turnover of EUR977 million (2009) Bayer HealthCare's
Animal Health Division is one of the world's leading manufacturers of
veterinary drugs. The division manufactures and markets more than 100
different veterinary drugs and care products for livestock and
companion animals.

Forward-Looking Statements

This news release contains forward-looking statements based on
current assumptions and forecasts made by Bayer Group management.
Various known and unknown risks, uncertainties and other factors
could lead to material differences between the actual future results,
financial situation, development or performance of the company and
the estimates given here. These factors include those discussed in
our annual and interim reports to the Frankfurt Stock Exchange and in
our reports filed with the U.S. Securities and Exchange Commission
(including our Form 20-F). The company assumes no liability
whatsoever to update these forward-looking statements or to confirm
them to future events or developments.

http://www.news.bayer.com

ots Originaltext: Bayer HealthCare
Im Internet recherchierbar: http://www.presseportal.de

Contact:
CONTACT: Contact: Bayer HealthCare AG, Corporate Communications,
51368Leverkusen, Germany, Phone +49-214-30-1